NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 7.4% during the 4th quarter, Holdings Channel reports. The firm owned 1,557,437 shares of the medical research company’s stock after selling 124,777 shares during the quarter. Emerald Advisers LLC’s holdings in NeoGenomics were worth $25,667,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in shares of NeoGenomics by 5.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company’s stock worth $257,000 after acquiring an additional 770 shares during the last quarter. FMR LLC boosted its stake in shares of NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after acquiring an additional 931 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock worth $73,000 after acquiring an additional 1,103 shares during the last quarter. KBC Group NV boosted its stake in shares of NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Versant Capital Management Inc boosted its stake in shares of NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after acquiring an additional 1,142 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Price Performance

NASDAQ:NEO opened at $9.86 on Friday. NeoGenomics, Inc. has a 52 week low of $8.98 and a 52 week high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.27 billion, a P/E ratio of -15.90 and a beta of 1.28. The stock’s fifty day moving average is $12.34 and its two-hundred day moving average is $14.57.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Equities analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on NEO shares. Bank of America reduced their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Needham & Company LLC reduced their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Piper Sandler reduced their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.